1
|
Martin MW, Lancia DR, Li H, Schiller SER, Toms AV, Wang Z, Bair KW, Castro J, Fessler S, Gotur D, Hubbs SE, Kauffman GS, Kershaw M, Luke GP, McKinnon C, Yao L, Lu W, Millan DS. Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN). Bioorg Med Chem Lett 2019; 29:1001-1006. [PMID: 30803804 DOI: 10.1016/j.bmcl.2019.02.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 02/05/2019] [Accepted: 02/10/2019] [Indexed: 12/29/2022]
Abstract
The discovery, structure-activity relationships, and optimization of a novel class of fatty acid synthase (FASN) inhibitors is reported. High throughput screening identified a series of substituted piperazines with structural features that enable interactions with many of the potency-driving regions of the FASN KR domain binding site. Derived from this series was FT113, a compound with potent biochemical and cellular activity, which translated into excellent activity in in vivo models.
Collapse
Affiliation(s)
- Matthew W Martin
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA.
| | - David R Lancia
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - Hongbin Li
- FORMA Therapeutics, 35 Northeast Industrial Road, Branford, CT 06405, USA
| | - Shawn E R Schiller
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - Angela V Toms
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - Zhongguo Wang
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - Kenneth W Bair
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - Jennifer Castro
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - Shawn Fessler
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - Deepali Gotur
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - Stephen E Hubbs
- FORMA Therapeutics, 35 Northeast Industrial Road, Branford, CT 06405, USA
| | - Goss S Kauffman
- FORMA Therapeutics, 35 Northeast Industrial Road, Branford, CT 06405, USA
| | - Mark Kershaw
- FORMA Therapeutics, 35 Northeast Industrial Road, Branford, CT 06405, USA
| | - George P Luke
- FORMA Therapeutics, 35 Northeast Industrial Road, Branford, CT 06405, USA
| | - Crystal McKinnon
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - Lili Yao
- FORMA Therapeutics, 35 Northeast Industrial Road, Branford, CT 06405, USA
| | - Wei Lu
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| | - David S Millan
- FORMA Therapeutics, 500 Arsenal Street, Suite 100, Watertown, MA 02472, USA
| |
Collapse
|
2
|
Soulère L, Alix PM, Croze ML, Soulage CO. Identification of novel antilipogenic agents targeting fatty acid biosynthesis through structure-based virtual screening. Chem Biol Drug Des 2018; 92:1366-1372. [PMID: 29635861 DOI: 10.1111/cbdd.13202] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Revised: 02/27/2018] [Accepted: 03/10/2018] [Indexed: 12/13/2022]
Abstract
An Asinex Gold Platinium chemical library subset of 12 055 compounds was screened employing docking simulations in the active site of the human FAS KS domain. Among them, 13 compounds were further evaluated for their ability to inhibit fatty acid biosynthesis. Four compounds were found to be active in particular ASN05064661 and ASN05374526 with IC50 values of 6.6 and 10.5 μm, respectively. A binding mode study was further conducted with these two compounds structurally related to benzene sulfonamide and aromatic polyamide. This study showed that they fit tightly with the active site with several interactions, notably with the key residues Cys161, His293, and His331.
Collapse
Affiliation(s)
- Laurent Soulère
- Univ Lyon, INSA Lyon, UMR 5246, CNRS, Université Lyon 1, CPE Lyon, ICBMS, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires, Villeurbanne, France
| | - Pascaline M Alix
- Univ Lyon, CarMeN Laboratory, Inserm U1060, INSA Lyon, INRA U1397, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - Marine L Croze
- Univ Lyon, CarMeN Laboratory, Inserm U1060, INSA Lyon, INRA U1397, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - Christophe O Soulage
- Univ Lyon, CarMeN Laboratory, Inserm U1060, INSA Lyon, INRA U1397, Université Claude Bernard Lyon 1, Villeurbanne, France
| |
Collapse
|
4
|
Crosby J, Crump MP. The structural role of the carrier protein--active controller or passive carrier. Nat Prod Rep 2012; 29:1111-37. [PMID: 22930263 DOI: 10.1039/c2np20062g] [Citation(s) in RCA: 132] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Common to all FASs, PKSs and NRPSs is a remarkable component, the acyl or peptidyl carrier protein (A/PCP). These take the form of small individual proteins in type II systems or discrete folded domains in the multi-domain type I systems and are characterized by a fold consisting of three major α-helices and between 60-100 amino acids. This protein is central to these biosynthetic systems and it must bind and transport a wide variety of functionalized ligands as well as mediate numerous protein-protein interactions, all of which contribute to efficient enzyme turnover. This review covers the structural and biochemical characterization of carrier proteins, as well as assessing their interactions with different ligands, and other synthase components. Finally, their role as an emerging tool in biotechnology is discussed.
Collapse
Affiliation(s)
- John Crosby
- School of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, UK
| | | |
Collapse
|
5
|
Abstract
The development of coimmobilized multi-enzymatic systems is increasingly driven by economic and environmental constraints that provide an impetus to develop alternatives to conventional multistep synthetic methods. As in nature, enzyme-based systems work cooperatively to direct the formation of desired products within the defined compartmentalization of a cell. In an attempt to mimic biology, coimmobilization is intended to immobilize a number of sequential or cooperating biocatalysts on the same support to impart stability and enhance reaction kinetics by optimizing catalytic turnover. There are three primary reasons for the utilization of coimmobilized enzymes: to enhance the efficiency of one of the enzymes by the in-situ generation of its substrate, to simplify a process that is conventionally carried out in several steps and/or to eliminate undesired by-products of an enzymatic reaction. As such, coimmobilization provides benefits that span numerous biotechnological applications, from biosensing of molecules to cofactor recycling and to combination of multiple biocatalysts for the synthesis of valuable products.
Collapse
Affiliation(s)
- Lorena Betancor
- Madrid Institute for Advanced Studies, Campus Universitario de Cantoblanco, Madrid, Spain.
| | | |
Collapse
|